🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementFAERS pharmacovigilance data for semaglutide — looking for input Page 3

FAERS pharmacovigilance data for semaglutide — looking for input

B12Beth Sun, Feb 8, 2026 at 6:51 AM 11 replies 898 viewsPage 3 of 3
amsterdam_pete
Senior Member
1,567
6,789
Feb 2024
Netherlands
Feb 11, 2026 at 8:59 PM#11
LipidDoc_ATL said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

10 8JakeSmashed95, NauseaFreeNow, SteveThurs and 7 others
Reply Quote Save Share Report
marcus_mpls
Member
234
1,123
Nov 2024
Minneapolis, MN
Feb 14, 2026 at 10:39 AM#12
sean_dublin said:
Steady state is the thing most people miss.

That reframing is the part I needed. Sending this to two other people who asked me the same thing last week.

Last edited: Feb 14, 2026 at 3:39 PM
11 9oliver_london, tane_welly, Dr.PathRoch and 8 others
Reply Quote Save Share Report
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
Feb 17, 2026 at 12:18 AM#13
LipidDoc_ATL said:
The distinction that resolves most of these threads is between what is true on average and what is true for one person.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

12 10BrianDallas92, labquiet_amy, emily_PDX and 9 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
quinn_sf
Member
489
2,123
Jun 2024
San Francisco, CA
Feb 19, 2026 at 1:56 PM#14

The figures, for anyone assembling their own picture. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

13 11andrew_nyc, Dr.EndoEP, GraceAZ_72 and 10 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Feb 22, 2026 at 3:32 AM#15

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

14 12PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 11 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register